Platform
Scientific centre.
Methodology, preclinical evidence and its limits. Our research programmes follow a shared in vivo development pathway; programme status does not demonstrate benefit in humans.
Preclinical evidence.
VivoXpand describes an in vivo platform with six mouse models, 200 compounds phenotypically tested and 170+ research experiments. These are platform-level totals, not clinical outcomes for an individual product.
Candidates are selected using scientific literature, internal datasets and AI tools. They are assessed in in vivo models, and findings inform formulation development. Our in vivo studies are carried out by VivoArchitect Sàrl, a contract research organisation (CRO) in Lausanne.
Preclinical research cannot by itself establish efficacy, safety or a health benefit in humans.
Evidence in humans.
No completed product-specific human study is documented in the material available for this page. This describes a documentation gap, not a conclusion that no study exists.
Human study registrations, protocols, participant characteristics, outcomes and publications remain to be verified. No human benefit is inferred from mouse studies.
What has been evaluated.
The programme table below records the research areas and stages described by VivoXpand. Programme labels identify research aims, not demonstrated effects. Selling, formulated, research and planned are development stages, not evidence grades.
The public material does not identify which model, dose, comparator or endpoint supports each formulation. These links must be documented before a product-specific result can be assessed.
Disclosable results and limitations.
Platform totals and programme status are available below. Product-specific effect sizes, sample sizes, uncertainty estimates, adverse observations and statistical analyses are not documented here.
Model species and strain, sex, age, controls, allocation, blinding, ethics approvals, exposure and reproducibility need verification at study level. A result should only be described together with its design and limitations.
Ongoing programmes.
Natural-compound formulations studied in preclinical in vivo models. Food supplement development route.
Status shows the furthest stage reached, out of six stages: Planned, Research, Formulated, Regulatory, Manufacturing, Selling.
| Programme | Product | Status | Route | Open for |
|---|---|---|---|---|
| Sleep qualityHeat and stress | SiestaK | Selling · stage 6 of 6 |
Own brand | On market |
| Sexual function · women | BLUFEM | Selling · stage 6 of 6 |
Own brand | On market |
| Sexual function · men | BluGent | Formulated · stage 3 of 6 |
Distribution | US distributors |
| Cold tolerance & performanceOutdoor work · winter sport | AlpineFlame | Research · stage 2 of 6 |
Licence | Licensing |
| Stress & anxiety | MenusStress | Research · stage 2 of 6 |
Own brand | In-house |
| Hedonic appetite | MenusAppetite | Planned · stage 1 of 6 |
Own brand | In-house |
| Male fertility | Fertilia Seminal | Planned · stage 1 of 6 |
Co-development | Co-development |
| Menopause symptoms | MenusPausia | Planned · stage 1 of 6 |
Co-development | Co-development |
Have another health problem in mind?
Ask us about a new programme.
Open now
Looking for partners and funding.
Licensing
AlpineFlame
Cold tolerance and performance. In research. For sports nutrition, outdoor work and winter sports.
Distribution
BluGent
Formulated. We are looking for distributors in the US; market-specific regulatory acceptance requires confirmation.
Co-development
Fertilia Seminal and MenusPausia
Male fertility and menopause. Planned. Open to co-development partners.
Investors
Fund a programme
Support a programme in research or planned, or open a new one with us.
How we work
From health problem to preclinical formulation assessment.
01
Identify the model
We pick health challenges that are not classified as diseases. Then we build in vivo models that reproduce them at the whole-body level, with phenotypic, physiologically relevant readouts.
02
Compound discovery
Using scientific literature, our own datasets and AI tools, we rank candidate compounds by their potential to act on the target biology.
03
Preclinical assessment and formulation
Candidates are tested in our models at our CRO. Findings in these models inform multi-compound formulation development; they do not establish benefit in humans.
Our in vivo studies are carried out by VivoArchitect Sàrl, a contract research organisation (CRO) in Lausanne.
Visit vivoarchitect.comQuestions and answers.
What does preclinical evidence mean?
Preclinical evidence comes from research before, or outside, studies designed to establish effects in humans. VivoXpand describes work in in vivo mouse models and compound discovery. Results apply to the conditions studied. They do not, by themselves, demonstrate that a food supplement is effective or safe for people, or establish an authorized health claim.
How are candidate compounds selected?
The platform describes ranking candidates using scientific literature, internal datasets and AI tools, followed by assessment in in vivo models. This describes the development process rather than a guarantee that a candidate will work. Compound identities, selection criteria, study protocols and formulation-specific results need documented sources before they can be assessed independently.
Where are the in vivo studies carried out?
The website identifies VivoArchitect Sàrl, a contract research organisation in Lausanne, as the service provider carrying out the in vivo studies. VivoXpand and the CRO have distinct roles. The scientific interpretation still depends on the specific model, protocol, controls, measurements and analysis; the location or provider alone does not establish the strength of evidence.
Are research totals proof that a product works?
No. The website reports six in vivo models, 200 compounds phenotypically tested and more than 170 research experiments as platform-level information. Those totals are not a product-specific clinical result. An assessment of a formulation requires the relevant protocol, comparator, sample size, outcomes, analysis and limitations, rather than an aggregate count across research programmes.
Is there evidence from studies in humans?
No completed product-specific human study is documented in the public material used for this scientific centre. That is a limit of the available documentation, not proof that no study exists. A human nutritional study is discussed as a possible partnership activity. Study registrations, methods, results and publications must be verified before describing human benefits.
What results can currently be assessed publicly?
The website describes the platform, research totals, programme names and development stages. It does not provide enough product-specific methods and quantitative results here for an independent assessment of efficacy or safety. Missing study reports, statistical analyses and references are recorded for verification. Research activity and commercial availability should not be interpreted as demonstrated clinical benefit.